Fig. 4
Long-term therapeutic efficacy of L-IFPTA+ vaccine in hypercholesterolemic C57BL/6 mice. a Evaluation of anti-PCSK9 antibody titers (ODmax/2) over 16 weeks post-prime vaccination, generated upon four immunizations in a bi-weekly interval (signed by arrows). Values are means ± SD, n = 7 mice/group. b Measurement of LDL-C levels over the same time period as a. Values are means; error bars represent SDs (n = 7 mice/group). To compare the L-IFPTA+ vaccine and control groups, two-way ANOVA test was used, followed by Bonferroni multiple comparisons test, at the indicated time points